ArticleBMC cancer2020
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron-Dependent PI3K/AKT/mTOR Signaling Pathway.Cancer science · 2025Article
- Salvage Structures, Known as Iron Chelating Agents, Acquired from the Nature and Matured in the Labs.Current medicinal chemistry · 2025Review
- Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells.Experimental & molecular medicine · 2024Article
- Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway.Hepatology international · 2024Article
- Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.BMC cancer · 2023Article
- Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases.Chemical Society reviews · 2023Review
- Targeting iron metabolism in osteosarcoma.Discover oncology · 2023Review
- Repurposed Drugs in Gastric Cancer.Molecules (Basel, Switzerland) · 2022Review
- Therapeutic potential of induced iron depletion using iron chelators in Covid-19.Saudi journal of biological sciences · 2022Review
- A DFX-based iron nanochelator for cancer therapy.Frontiers in bioengineering and biotechnology · 2022Article
- Iron Metabolism and Immune Regulation.Frontiers in immunology · 2022Review
- The Impact of Iron Chelators on the Biology of Cancer Stem Cells.International journal of molecular sciences · 2021Review
- Article
- Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021Article
- Collective Polarization of Cancer Cells at the Monolayer Boundary.Micromachines · 2021Article
- Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.International journal of biological sciences · 2021Article
- Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment.Oxidative medicine and cellular longevity · 2021Review
- Iron and Cancer: 2020 Vision.Cancer research · 2020Review
Corrections and comments
- Retraction · 2023-12-11Concerns/Issues about Data · Concerns/Issues about Image · Duplication of/in Image · Error in Image · Euphemisms for Duplication · Investigation by Journal/Publisher · Unreliable Data · Upgrade/Update of Prior Notice(s) · · See also: https://pubpeer.com/publications/11C16030FE8525FCD1BD80511A06F3
- Correction · 2023-06-23Duplication of/in Image · Error in Image · Euphemisms for Duplication · Updated to Retraction · · See also: https://pubpeer.com/publications/11C16030FE8525FCD1BD80511A06F3
- Erratum issued
- Retracted
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIron is required for cellular metabolism, and rapidly proliferating cancer cells require more of this essential nutrient. Therefore, iron regulation may well represent a new avenue for cancer therapy. We have reported, through in vitro and in vivo research involving pancreatic cancer cell lines, that the internal-use, next-generation iron chelator deferasirox (DFX) exhibits concentration-dependent tumour-suppressive effects, among other effects. After performing a microarray analysis on the tumour grafts used in that research, we found that DFX may be able to suppress the cellular movement pathways of pancreatic cancer cells. In this study, we conducted in vitro analyses to evaluate the effects of DFX on the invasive and migratory abilities of pancreatic cancer cells.
methodsWe used pancreatic cancer cell lines (BxPC-3, Panc-1, and HPAF II) to examine the efficacy of DFX in preventing invasion in vitro, evaluated using scratch assays and Boyden chamber assays. In an effort to understand the mechanism of action whereby DFX suppresses tumour invasion and migration, we performed G-LISA to examine the activation of Cdc42 and Rac1 which are known for their involvement in cellular movement pathways.
resultsIn our scratch assays, we observed that DFX-treated cells had significantly reduced invasive ability compared with that of control cells. Similarly, in our Boyden chamber assays, we observed that DFX-treated cells had significantly reduced migratory ability. After analysis of the Rho family of proteins, we observed a significant reduction in the activation of Cdc42 and Rac1 in DFX-treated cells.
conclusionsDFX can suppress the motility of cancer cells by reducing Cdc42 and Rac1 activation. Pancreatic cancers often have metastatic lesions, which means that use of DFX will suppress not only tumour proliferation but also tumour invasion, and we expect that this will lead to improved prognoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.